Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...
Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease’s progression - ...
Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...
The Food and Drug Administration is set to treat the application under its priority program to accelerate the review of ...
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...
The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.25%) hit a four-year low Monday, falling below $44 a ...
6don MSN
Novo Nordisk shares plunge to four-year low after Alzheimer's drug trial fails to hit key target
Shares of Novo Nordisk plunged after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's ...
Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 ...
Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...
While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, ...
Fintel reports that on November 28, 2025, Goldman Sachs maintained coverage of Novo Nordisk A (NYSE:NVO) with a Buy ...
Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. The company revealed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback